Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Evaluation of randomized discontinuation designBoris Freidlin, Richard Simon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patientsBoris Freidlin, Richard Simon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatmentsEdward L Korn, Boris Freidlin
The American Journal of Bioethics : AJOB|March 15, 2011
Inefficacy interim monitoring procedures in randomized clinical trials: the need to reportEdward L Korn, Boris Freidlin
Clinical Trials (London, England)|July 22, 2016
Non-factorial analyses of two-by-two factorial trial designsEdward L Korn, Boris Freidlin
Biometrics|October 25, 2016
Reader reaction on estimation of treatment effects in all-comers randomized clinical trials with a predictive markerEdward L Korn, Boris Freidlin
Lancet (London, England)|July 11, 2003
Targeting epidermal growth factor receptor--are we missing the mark?Janet E Dancey, Boris Freidlin
Journal of the National Cancer Institute|September 26, 2022
Augmenting randomized clinical trial data with historical control data: Precision medicine applicationsBoris Freidlin, Edward L Korn
Statistics in Medicine|May 26, 2004
A testing procedure for survival data with few respondersBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|July 21, 2021
A Problematic Biomarker Trial DesignBoris Freidlin, Edward L Korn
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Evaluation of randomized discontinuation designBoris Freidlin, Richard Simon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patientsBoris Freidlin, Richard Simon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatmentsEdward L Korn, Boris Freidlin
The American Journal of Bioethics : AJOB|March 15, 2011
Inefficacy interim monitoring procedures in randomized clinical trials: the need to reportEdward L Korn, Boris Freidlin
Clinical Trials (London, England)|July 22, 2016
Non-factorial analyses of two-by-two factorial trial designsEdward L Korn, Boris Freidlin
Biometrics|October 25, 2016
Reader reaction on estimation of treatment effects in all-comers randomized clinical trials with a predictive markerEdward L Korn, Boris Freidlin
Lancet (London, England)|July 11, 2003
Targeting epidermal growth factor receptor--are we missing the mark?Janet E Dancey, Boris Freidlin
Journal of the National Cancer Institute|September 26, 2022
Augmenting randomized clinical trial data with historical control data: Precision medicine applicationsBoris Freidlin, Edward L Korn
Statistics in Medicine|May 26, 2004
A testing procedure for survival data with few respondersBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|July 21, 2021
A Problematic Biomarker Trial DesignBoris Freidlin, Edward L Korn
Pageof 12